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challenged by payers and regulatory authorities to develop evidence describing 
the burden of illness and justifying the payer investment.  
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OBJECTIVES: Determine the relationship between health care expenditures and 
depression in individuals with cancer compared to those with cancer and 
depression, after controlling for demographic, socio-economic, access to care 
and other health status variables. METHODS: Cross-sectional data on 4766 adults 
from multiple years (2006, 2007, 2008, and 2009) of the nationally representative 
household survey, Medical Expenditure Panel Survey (MEPS) were used. Cancer 
and depression was identified from Medical conditions file. Dependent variables 
consisted of total, inpatient, outpatient, emergency room, prescription drugs and 
other expenditures. OLS on logged dollars and generalized linear models with 
log-link were performed. All analyses accounted for the complex survey design 
of the MEPS. RESULTS: Overall, 14% of individuals with cancer reported having 
depression. Among individuals with cancer and depression the average health 
care expenditures were $18,401compared to $12,091 among those without 
depression. After adjusting for demographic, socio-economic, access to care and 
other health status variables, those with depression had about 32% greater total 
expenditures compared to those without depression. Expenditures for every type 
were higher among individuals with depression compared to those without 
depression. Individuals with cancer and depression were more significantly 
more likely to use emergency rooms (AOR = 1.46) and prescription drugs (AOR = 
3.56) compared to their counterparts without depression. CONCLUSIONS: Among 
adults with cancer, those with depression had higher health care utilization and 
expenditures compared to those without depression. Policy efforts to reduce 
excess health care expenditures associated with depression may include 
screening for depressive symptoms and preventing major depression, timely 
depression treatment once depression is detected.  
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OBJECTIVES: Following FDA approval, medical technology must still gain Centers 
for Medicare and Medicaid Services (CMS) coverage before Medicare 
reimbursement. However, the two agencies use approval processes based on 
different evidentiary standards. We identified the type and nature of 
discrepancies between FDA approval and CMS national coverage determinations 
(NCDs) for drugs and devices. METHODS: We used the Tufts Medical Center NCD 
database, which contains detailed information on 165 NCDs since 1999. For each 
device or Part B drug considered in an NCD (1999-2011) (n=69), we searched the 
FDA website to identify the approved indication. We classified CMS coverage as: 
more restrictive than FDA approval, i.e., conditions were placed on coverage 
beyond the FDA-approved label; equivalent to FDA approval; or less restrictive than 
FDA approval, i.e., CMS covers off-label indications. Further, we categorized 
conditions placed on CMS coverage as: “patient-related”, e.g., restricted to patients 
with certain comorbidities or characteristics; “place in therapy”, e.g., tied to use as 
second-line therapy; or “technology-related”, e.g., restricted to a particular 
application of the drug or device. RESULTS: CMS has covered FDA-approved 
drugs or devices taken through the Medicare NCD process in 80% of cases (55/69). 
For CMS covered drugs and devices (n=55), coverage was more restrictive in 32 
cases (58%), equivalent to FDA approval/clearance in 16 (29%), and less restrictive 
in seven (13%). Most common coverage restrictions were patient-related (78%), 
e.g., laparoscopic gastric banding to treat obesity is covered for patients suffering 
from an obesity-related comorbidity, and place in therapy (38%), e.g., coverage for 
extracorporeal immunoadsorption is covered for rheumatoid arthritis patients 
who have failed three disease-modifying antirheumatic drugs (DMARDs). In 
roughly one third of cases, CMS placed multiple restrictions on coverage. 
CONCLUSIONS: CMS coverage determinations are generally more restrictive 
than corresponding FDA approval. CMS often restricts coverage to patients with 
the most severe disease.  
 
HC4  
HOSPITALIZATION COSTS AND OUTCOMES AMONG ELDERLY CANCER 
PATIENTS IN THE UNITED STATES  
Khanna R1, Jariwala K2, Bentley JP1, Patel A3 
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA, 
3Medical Marketing Economics, LLC, Oxford, MS, USA  
OBJECTIVES: To assess the patient-, hospital-, and discharge-level 
characteristics, and hospitalization rates among elderly patients with cancer in 
the United States (US). Hospitalization outcomes (length of stay [LOS], total 
charges, and mortality) among elderly patients with cancer were also studied. 
METHODS: A cross-sectional descriptive analysis of the 2009 Healthcare Cost 
and Utilization Project (HCUP) database was conducted. Patients were identified 
based on diagnosis (any-listed) of cancer using Clinical Classification Software 
(CCS). A control group of patients without cancer were identified by matching on 
age and gender (1:2 case-control). Analyses were conducted using PROC SURVEY 
procedures in SAS v9.2. RESULTS: In 2009, a total of 3,325,174 (weighted) 
hospitalizations occurred among elderly patients with cancer in the US. Elderly 
cancer patients had higher total hospital charges ($39,406 vs. $37,756), longer LOS 
(5.7 days vs. 5.4 days), and higher mortality (4.8% vs. 3.6%) as compared to those 
without cancer. A greater proportion of hospitalizations among cancer patients 
occurred in teaching hospitals (44.1% vs. 38.9%; p<0.001). In terms of location, a 
greater proportion of hospitalizations for cancer patients occurred in hospitals 
located in urban areas in comparison to those without cancer (88.1% vs. 84.7%; 
p<0.001). Total charges for hospitalizations among elderly patients with prostate 
(average LOS=4.9 days), lung (average LOS=6.1 days), and breast cancer (average 
LOS=4.9 days) were roughly $19.2, $16.1, and $16.0 billion, respectively. Mortality 
rates during hospitalization were the highest for those with pancreatic (10%), 
liver (9.7%), and lung cancer (8.7%). CONCLUSIONS: Elderly patients with cancer 
had significantly greater hospitalization burden as compared to those without 
cancer. Hospital mortality rates were the highest for elderly patients with 
pancreatic, liver, and lung cancer, respectively.  
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Inter-country variability in access to orphan drugs across countries has been 
highlighted in a number of studies. Understanding the reasons driving coverage 
decisions is a way forward in identifying areas where HTA methods may be 
improved. OBJECTIVES: Objectives are three-fold: a) to establish a 
methodological framework enabling to systematically compare HTA processes 
across countries; b) to identify the criteria driving HTA recommendations for a 
sample of orphan drugs, and; c) to understand the reasons for diverging 
recommendations and propose ways to minimize these. METHODS: All common 
orphan drug-indication pairs appraised in six countries (England, Scotland, 
France, Sweden, Canada and Australia) between 2001 and 2012 were selected. 
Agreement levels in HTA outcomes between countries were measured using 
Cohen’s kappa scores. Thematic analysis, by creating an NVivo-9 coding manual, 
was conducted to systematically compare each compound. Reasons for diverging 
HTA outcomes were differentiated based on whether they are a consequence of 
country-specific considerations or of the HTA process, and ranked by frequency 
of occurrences. RESULTS: Fourteen orphan drug-indication pairs were retrieved. 
Agreement in HTA outcomes was poor (k = [-0.5; 0.3]). Eight drug-indication pairs 
appraised by at least four HTA bodies were analyzed, five of which received 
diverging outcomes. Preliminary results suggest that in four of five cases, 
reasons for diverging recommendations were a consequence of the HTA process. 
Examples of non-homogeneous assessments include: lack of appropriate 
primary endpoint, lack of long-term data, evidence not reflecting clinical 
practice, orphan status or unmet clinical need. CONCLUSIONS: Preliminary 
results identify the criteria driving the assessments and reasons why they result 
in diverging HTA outcomes, enabling a better understanding of these processes 
by elucidating the expectations and value judgments from HTA bodies, 
particularly on the orphan status, and identifying areas where more consensus 
on what constitutes appropriate HTA methodologies is needed. Final results will 
quantify these criteria in a systematic manner.  
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OBJECTIVES: HTA agencies often review the same drugs for the same/similar 
indications. How often do agencies agree on their reimbursement decisions? 
Previous research has compared reimbursement recommendations (for the same 
drugs) for a limited number of agencies, but studies have rarely focused on more 
than 2 agencies. We collect and analyze a large number of health technology 
assessments from several countries to explore how often the agencies agree on 
their reimbursement decisions. METHODS: The data covered five agencies that 
make reimbursement decisions: NICE, SMC, PBAC, HAS and CADTH’s Common 
Drug Review. Our analysis only included decisions for drugs that were reviewed 
by at least two agencies. If a drug was reviewed multiple times by an agency for 
the same indication (i.e. resubmissions or updates) we used the most recent 
review for the analysis. A total of 78 drugs were reviewed by at least 2 agencies, 
producing a total of 195 reviews. RESULTS: There was generally a high level of 
agreement between all pairs of agencies, ranging from 56% (PBAC; CADTH) to 
91% (NICE; HAS). It is important to note that within the sample of drugs 
reviewed, all agencies issued positive recommendations at very high rates – all 
but CADTH issued positive recommendations for more than 80% of the drugs 
reviewed. This fact alone would produce high levels of agreement, even if 
agencies’ recommendations were statistically independent. Actual agreement 
rates observed were close to those implied by independence. CONCLUSIONS: 
Agencies agree on their reimbursement decisions quite often, but at rates close 
to those implied by their high overall positive recommendation rates alone. 
Future research will focus on identifying the determinants of agencies’ high 
rates of agreement.  
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